Loading clinical trials...
Loading clinical trials...
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Health Network, Toronto
NCT07004582 · Prostate Cancer, Prostate Cancer Metastatic Disease, and more
NCT07426094 · Prostate Cancer, Brachytherapy, and more
NCT06895291 · Lymphoma, Advanced Prostate Cancer, and more
NCT06387056 · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
NCT05406999 · Neoadjuvant Therapy, High Risk Prostate Cancer, and more
Princess Margaret Cancer Centre
Toronto, Ontario
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions